# A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

> **NCT03336216** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 205 (actual)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Cabiralizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Onivyde
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Fluorouracil
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan Hydrochloride

## Key facts

- **NCT ID:** NCT03336216
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336216, "A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03336216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*